Baxter International (BAX) Stock Price

Baxter International Price

NYSE·CLOSED
27.01USD-0.60 (-2.22 %)
Market closed

Over the last 19 years Baxter International grew revenue by 0.4% annually, reaching 11.24 B USD. Earnings per share have grown at 5.5% per year over the last 17 years. For Baxter International, the net margin of -8.5% is down versus 10.6% a few years ago. At today's price the dividend yield works out to roughly 1.93%. The consensus 12-month price target for Baxter International is 22.44 USD, about 16.9% below where the stock trades today. Of 25 analysts, 2 rate the stock a buy — an overall Hold consensus. The stock trades about 71% above its 52-week low.

Baxter International stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Baxter International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Baxter International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Baxter International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Baxter International Stock Price History
DateBaxter International Price
8/6/202627.01 USD
8/5/202627.61 USD
8/4/202627.70 USD
8/3/202628.10 USD
7/31/202626.16 USD
7/30/202626.75 USD
7/29/202624.73 USD
7/27/202623.28 USD
7/23/202621.67 USD
7/22/202621.74 USD
7/21/202622.21 USD
7/20/202622.07 USD
7/17/202622.61 USD
7/16/202623.35 USD
7/15/202622.15 USD
7/14/202621.80 USD
7/13/202622.73 USD
7/10/202622.62 USD
7/9/202622.46 USD
7/8/202622.33 USD
7/7/202622.86 USD
7/6/202622.28 USD
7/2/202622.65 USD
7/1/202621.69 USD
6/30/202621.32 USD
6/29/202622.00 USD
6/26/202622.04 USD
6/25/202621.55 USD
6/24/202621.04 USD
6/23/202620.10 USD
6/22/202619.82 USD
6/18/202619.96 USD
6/17/202620.24 USD
6/16/202620.58 USD
6/15/202620.97 USD
6/12/202620.71 USD
6/11/202620.16 USD
6/10/202620.57 USD
6/9/202620.03 USD
6/8/202619.24 USD
6/5/202619.68 USD
6/4/202619.22 USD
6/3/202618.45 USD
6/2/202618.95 USD
6/1/202618.31 USD
5/29/202619.10 USD
5/28/202619.17 USD
5/27/202619.65 USD
5/26/202619.40 USD
5/22/202619.15 USD
5/21/202618.69 USD
5/20/202618.32 USD
5/19/202618.33 USD
5/18/202617.79 USD
5/15/202617.30 USD
5/14/202617.78 USD
5/13/202617.31 USD
5/12/202617.89 USD
5/11/202617.53 USD
5/8/202617.99 USD
5/7/202617.49 USD
5/6/202616.98 USD
5/5/202616.75 USD
5/4/202616.62 USD
5/1/202617.21 USD
4/30/202617.58 USD
4/29/202616.90 USD
4/28/202617.94 USD
4/27/202618.49 USD
4/24/202618.16 USD
4/23/202618.41 USD
4/22/202618.31 USD
4/21/202618.49 USD
4/20/202618.84 USD
4/17/202618.71 USD
4/16/202618.14 USD
4/15/202617.60 USD
4/14/202617.59 USD
4/13/202617.63 USD
4/10/202617.15 USD
4/9/202617.30 USD
4/8/202617.24 USD
4/7/202616.62 USD
4/6/202616.65 USD
4/2/202616.68 USD
4/1/202616.78 USD
3/31/202616.80 USD
3/30/202615.80 USD
3/27/202615.97 USD
3/26/202616.67 USD
3/25/202617.12 USD
3/24/202616.72 USD
3/23/202616.61 USD
3/20/202616.15 USD
3/19/202616.66 USD
3/18/202617.09 USD
3/17/202617.62 USD
3/16/202617.08 USD
3/13/202617.40 USD
3/12/202618.01 USD
3/11/202618.05 USD
3/10/202617.46 USD
3/9/202617.91 USD
3/6/202617.69 USD
3/5/202618.60 USD
3/4/202619.03 USD
3/3/202619.03 USD
3/2/202619.69 USD
2/27/202620.37 USD
2/26/202620.36 USD
2/25/202620.73 USD
2/24/202620.63 USD
2/23/202621.26 USD
2/20/202621.58 USD
2/19/202621.34 USD
2/18/202621.87 USD
2/17/202620.74 USD
2/13/202619.79 USD
2/12/202618.71 USD
2/11/202622.27 USD
2/10/202621.94 USD
2/9/202621.73 USD
2/6/202621.73 USD
2/5/202621.77 USD
2/4/202621.03 USD
2/3/202619.91 USD
2/2/202619.87 USD
1/30/202620.07 USD
1/29/202619.73 USD
1/28/202619.61 USD
1/27/202619.57 USD
1/26/202619.65 USD
1/23/202619.84 USD
1/22/202620.07 USD
1/21/202619.71 USD
1/20/202619.38 USD
1/16/202620.11 USD
1/15/202620.37 USD
1/14/202619.84 USD
1/13/202619.65 USD
1/12/202620.15 USD
1/9/202621.07 USD
1/8/202620.69 USD
1/7/202620.40 USD
1/6/202620.55 USD
1/5/202619.89 USD
1/2/202619.50 USD
12/31/202519.11 USD
12/30/202519.30 USD
12/29/202519.25 USD
12/26/202519.38 USD
12/24/202519.11 USD
12/23/202518.93 USD
12/22/202518.98 USD
12/19/202518.96 USD
12/18/202519.07 USD
12/17/202519.29 USD
12/16/202519.05 USD
12/15/202519.53 USD
12/12/202519.15 USD
12/11/202518.90 USD
12/10/202518.26 USD
12/9/202518.16 USD
12/8/202518.16 USD
12/5/202518.54 USD
12/4/202518.48 USD
12/3/202518.89 USD
12/2/202518.84 USD
12/1/202519.08 USD
11/28/202518.74 USD
11/26/202518.91 USD
11/25/202518.66 USD
11/24/202518.18 USD
11/21/202518.31 USD
11/20/202517.42 USD
11/19/202517.69 USD
11/18/202518.15 USD
11/17/202517.77 USD
11/14/202518.47 USD
11/13/202518.70 USD
11/12/202518.70 USD
11/11/202518.25 USD
11/10/202517.75 USD
11/7/202518.00 USD
11/6/202517.98 USD
11/5/202517.95 USD
11/4/202517.94 USD
11/3/202518.21 USD
10/31/202518.47 USD
10/30/202519.16 USD
10/29/202522.42 USD
10/28/202522.86 USD
10/27/202523.17 USD
10/24/202523.02 USD
10/23/202522.99 USD
10/22/202522.93 USD
10/21/202522.75 USD
10/20/202523.13 USD
10/17/202523.09 USD
10/16/202522.97 USD
10/15/202522.75 USD
10/14/202522.82 USD
10/13/202522.11 USD
10/10/202521.95 USD
10/9/202522.51 USD
10/8/202522.75 USD
10/7/202522.90 USD
10/6/202523.15 USD
10/3/202523.86 USD
10/2/202523.23 USD
10/1/202523.36 USD
9/30/202522.77 USD
9/29/202522.38 USD
9/26/202521.98 USD
9/25/202521.71 USD
9/24/202522.56 USD
9/23/202522.86 USD
9/22/202522.81 USD
9/19/202523.02 USD
9/18/202523.69 USD
9/17/202523.20 USD
9/16/202523.87 USD
9/15/202523.80 USD
9/12/202523.99 USD
9/11/202524.49 USD
9/10/202523.98 USD
9/9/202524.45 USD
9/8/202524.09 USD
9/5/202524.42 USD
9/4/202523.58 USD
9/3/202523.54 USD
9/2/202524.17 USD
8/29/202524.69 USD
8/28/202524.40 USD
8/27/202524.53 USD
8/26/202524.50 USD
8/25/202524.56 USD
8/22/202524.54 USD
8/21/202523.85 USD
8/20/202524.27 USD
8/19/202524.33 USD
8/18/202523.61 USD
8/15/202524.18 USD
8/14/202524.45 USD
8/13/202524.11 USD
8/12/202523.98 USD
8/11/202523.46 USD
Access this data via the Eulerpool API

Baxter International Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
12.15 B USD
1.35 B USD
1.28 B USD
Jan 1, 2022
10.06 B USD
-2.84 B USD
-2.43 B USD
Jan 1, 2023
10.36 B USD
707.00 M USD
2.66 B USD
Jan 1, 2024
10.64 B USD
14.00 M USD
-649.00 M USD
Jan 1, 2025
11.24 B USD
-267.00 M USD
-957.00 M USD
Jan 1, 2026 (e)
11.35 B USD
-246.35 M USD
980.13 M USD
Jan 1, 2027 (e)
11.58 B USD
-251.28 M USD
1.01 B USD
Jan 1, 2028 (e)
11.90 B USD
-258.35 M USD
1.09 B USD

Baxter International Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 12:31 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
9.4110.729.9710.1610.5811.1011.3611.6712.1510.0610.3610.6411.2411.3511.5811.90
-32.4613.87-7.011.964.144.872.372.744.05-17.203.012.665.720.952.002.82
44.2242.7441.5940.5042.2742.8841.9039.3038.8635.2940.0637.4630.0530.0530.0530.05
4.164.584.154.124.474.764.764.594.723.554.153.983.383.413.483.58
0.500.660.450.751.291.711.081.621.35-2.840.710.01-0.27-0.25-0.25-0.26
5.276.124.507.3312.1715.419.5113.8411.11-28.196.820.13-2.37-2.17-2.17-2.17
2.012.500.974.970.601.551.001.101.28-2.432.66-0.65-0.960.981.011.09
-13.5024.11-61.23412.91-87.88156.81-35.2510.0916.52-289.49-209.17-124.4447.46-202.402.868.33
1.922.051.270.510.610.730.850.961.091.151.161.040.520.040.040.04
22.296.77-38.05-59.8419.6119.6716.4411.7613.686.480.87-10.34-50.00-92.31
548.00547.00550.00551.00556.00538.00516.00516.00507.00507.00507.00510.00514.00514.00514.00514.00
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Baxter International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Baxter International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Baxter International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Baxter International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Baxter International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Baxter International stock margins

The Baxter International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Baxter International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Baxter International.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
38.86 %
11.11 %
10.57 %
Jan 1, 2022
35.29 %
-28.19 %
-24.19 %
Jan 1, 2023
40.06 %
6.82 %
25.64 %
Jan 1, 2024
37.46 %
0.13 %
-6.10 %
Jan 1, 2025
30.05 %
-2.37 %
-8.51 %
Jan 1, 2026 (e)
30.05 %
-2.17 %
8.63 %
Jan 1, 2027 (e)
30.05 %
-2.17 %
8.71 %
Jan 1, 2028 (e)
30.05 %
-2.17 %
9.17 %

Baxter International Stock Revenue, EBIT, Earnings per Share

The Baxter International earnings per share therefore indicates how much revenue Baxter International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
23.96 USD
2.66 USD
2.53 USD
Jan 1, 2022
19.84 USD
-5.59 USD
-4.80 USD
Jan 1, 2023
20.43 USD
1.39 USD
5.24 USD
Jan 1, 2024
20.85 USD
0.03 USD
-1.27 USD
Jan 1, 2025
21.88 USD
-0.52 USD
-1.86 USD
Jan 1, 2026 (e)
22.26 USD
-0.48 USD
1.92 USD
Jan 1, 2027 (e)
22.70 USD
-0.49 USD
1.98 USD
Jan 1, 2028 (e)
23.34 USD
-0.50 USD
2.14 USD

Baxter International business model & stock analysis

Baxter International Inc is a global company specialized in the development, manufacturing, and marketing of medical therapy products to improve the lives of patients worldwide. It was originally founded in 1931 as the American Hospital Supply Corporation. Since then, the company has continuously evolved and is now a leading provider of medical products and services. The company's history began in 1931 with the founding of the American Hospital Supply Corporation in Illinois. Over the years, the company acquired several small companies and expanded its range of medical products and services. In 1985, the company changed its name to Baxter Travenol Laboratories, Inc. and merged with Travenol Laboratories, Inc. Finally, in 1995, it was renamed Baxter International Inc. to reflect the international focus of the company. Baxter International Inc can be considered as a manufacturer and supplier of medical products in various areas of healthcare. The company is divided into several divisions to better structure and organize its different product and service offerings. The main divisions of the company are infusion systems and devices, parenteral nutrition, renal care products, biopharmaceuticals, and drug delivery systems and bottles. The infusion systems and devices division represents the largest share of Baxter International Inc's revenue. This division is involved in the manufacturing and marketing of products such as infusion pumps and tubing systems, which allow the precise and controlled delivery of fluids and medications into a patient's body. Another important area of Baxter International Inc is the manufacturing of parenteral nutrition. This involves the production of complex nutrient mixtures that are directly injected into the patient's vein when they are unable to receive nutrients in other ways. The company offers a variety of parenteral nutrition solutions enriched with carbohydrates, amino acids, and fats. The renal care products division of Baxter International is specialized in the development and manufacturing of devices and materials necessary for dialysis. Baxter International offers a wide range of dialysis machines and solutions that can be used in the treatment of patients with kidney problems. The company has also developed an extensive range of pediatric devices and solutions to meet the needs of children and adults. The biopharmaceuticals division of Baxter International Inc. focuses on the development and production of innovative medications. The company has a particular focus on the treatment of diseases such as hemophilia and immune disorders. Baxter International Inc. also distributes therapies that can be used to treat various diseases such as cancer or neurological disorders. The drug delivery systems and bottles division is responsible for the manufacturing of accessories, including bottles, bags, and connectors. The company develops and produces a variety of products focusing on drug administration, such as specialized bottles and syringes. Baxter International Inc. offers a wide range of products aimed at improving the health and lives of patients. In addition to infusion pumps and parenteral nutrition, the company also provides wound care devices, blood donation systems, vaccines, and much more. Product development is always tailored to the needs of end-users to ensure the highest possible quality of products and services. In conclusion, Baxter International Inc has established itself as a leading company in the medical and healthcare industry. The expansion of its product range, international focus, and emphasis on meeting the needs of end-users have contributed to the company's continuous growth and success. Furthermore, the company has made a significant contribution to improving healthcare worldwide through its products and services.

Baxter International SWOT Analysis

Strengths

1. Strong Market Position: Baxter International Inc holds a significant market share in the healthcare industry, especially in the field of medical devices and pharmaceuticals.

2. Diverse Product Portfolio: The company offers a wide range of products, including renal therapies, anesthesia products, surgical equipment, and pharmaceuticals, which helps in catering to different customer needs.

3. Global Presence: Baxter has a strong global presence, with operations in multiple countries, allowing it to capitalize on emerging markets and diverse customer base.

Weaknesses

1. Product Recalls: Baxter has faced product recalls in the past, which have affected its reputation and consumer confidence. The company needs to focus on improving its quality control processes.

2. Dependence on Key Customers: Baxter has a significant reliance on a few key customers for a substantial portion of its revenue. This dependency poses a risk if those customers choose to shift to competitors or face financial difficulties.

3. High R&D Costs: The research and development expenses of Baxter are substantial, and the company needs to ensure that the investments result in successful product innovations and market differentiation.

Opportunities

1. Growing Aging Population: With the global population aging, there is a growing demand for healthcare products and services, creating an opportunity for Baxter to expand its customer base.

2. Increasing Healthcare Expenditure: Governments and individuals are allocating more funds towards healthcare expenditure, providing an opportunity for Baxter to generate higher sales and revenues.

3. Technological Advancements: Advancements in technology, such as telemedicine and digital health platforms, present opportunities for Baxter to develop innovative products and solutions to meet the changing needs of healthcare providers and patients.

Threats

1. Intense Competition: Baxter operates in a highly competitive industry, facing competition from both established players and new entrants. This competition can impact market share and pricing power.

2. Regulatory Compliance: Compliance with stringent regulations and varying healthcare policies across different countries can create challenges for Baxter in terms of product approvals, pricing, and market access.

3. Economic Factors: Global economic instability, currency fluctuations, and healthcare budget cuts in certain regions can pose threats to Baxter's financial performance and growth prospects.

Baxter International Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Baxter International Employees
Details
Date
Baxter International Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Baxter International Segments

Baxter International Revenue by Segment (1/6)

  • 3 Years

  • Max

Renal Care
Medication Delivery
Pharmaceuticals
Patient support systems
Front line care
Advanced Surgery
Clinical Nutrition
Acute Therapies
BioPharma Solutions
Surgical solutions
Other
Details
Date
Renal Care
Medication Delivery
Pharmaceuticals
Patient support systems
Front line care
Advanced Surgery
Clinical Nutrition
Acute Therapies
BioPharma Solutions
Surgical solutions
Other
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
3.75 B USD
2.89 B USD
2.13 B USD
1.49 B USD
1.15 B USD
998.00 M USD
931.00 M USD
701.00 M USD
644.00 M USD
304.00 M USD
140.00 M USD

Baxter International Revenue by Segment (2/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Renal Care
Renal
Medication Delivery
Fluid systems
Pharmaceuticals
Integrate pharmacy solutions
Patient support systems
Surgical care
Front line care
Advanced Surgery
Clinical Nutrition
Nutrition
Acute Therapies
BioPharma Solutions
Acute theapies
Other product or services
Other segment
Surgical solutions
Other
Details
Date
Renal Care
Renal
Medication Delivery
Fluid systems
Pharmaceuticals
Integrate pharmacy solutions
Patient support systems
Surgical care
Front line care
Advanced Surgery
Clinical Nutrition
Nutrition
Acute Therapies
BioPharma Solutions
Acute theapies
Other product or services
Other segment
Surgical solutions
Other
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
2.11 B USD
0.00 USD
2.30 B USD
0.00 USD
1.32 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
453.00 M USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
2.30 B USD
0.00 USD
2.25 B USD
0.00 USD
1.32 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
442.00 M USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
3.48 B USD
2.70 B USD
0.00 USD
1.88 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
707.00 M USD
0.00 USD
882.00 M USD
0.00 USD
0.00 USD
456.00 M USD
455.00 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
3.90 B USD
0.00 USD
2.88 B USD
0.00 USD
2.29 B USD
0.00 USD
115.00 M USD
0.00 USD
70.00 M USD
977.00 M USD
964.00 M USD
0.00 USD
782.00 M USD
669.00 M USD
0.00 USD
0.00 USD
0.00 USD
27.00 M USD
109.00 M USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Baxter International Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • Max

Renal
Medication delivery
Pharmaceuticals
Clinical nutrition
Advanced surgery
Acute theapies
Other product or services
Details
Date
Renal
Medication delivery
Pharmaceuticals
Clinical nutrition
Advanced surgery
Acute theapies
Other product or services
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
3.66 B USD
2.67 B USD
2.09 B USD
877.00 M USD
800.00 M USD
517.00 M USD
510.00 M USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Baxter International Revenue by Segment (4/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Medical products
Americas
Bio science
Hospital products
Renal
EMEA
Hillrom
Europe, Middle East and Africa
APAC
Details
Date
Medical products
Americas
Bio science
Hospital products
Renal
EMEA
Hillrom
Europe, Middle East and Africa
APAC
Business Segment Other Member
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
2.30 B USD
3.79 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
6.31 B USD
3.86 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
5.72 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.73 B USD
2.11 B USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
6.09 B USD
0.00 USD
0.00 USD
0.00 USD
2.97 B USD
0.00 USD
0.00 USD
2.30 B USD
0.00 USD
Jan 1, 2020
0.00 USD
6.07 B USD
0.00 USD
0.00 USD
0.00 USD
3.13 B USD
0.00 USD
0.00 USD
2.48 B USD
0.00 USD
Jan 1, 2021
0.00 USD
6.67 B USD
0.00 USD
0.00 USD
0.00 USD
3.12 B USD
212.00 M USD
0.00 USD
2.79 B USD
0.00 USD
Jan 1, 2022
0.00 USD
6.71 B USD
0.00 USD
0.00 USD
0.00 USD
2.88 B USD
0.00 USD
0.00 USD
2.59 B USD
0.00 USD

Baxter International Revenue by Segment (5/6)

  • 3 Years

  • Max

Hillrom
Details
Date
Hillrom
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
2.94 B USD

Baxter International Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • Max

Americas
EMEA
APAC
Details
Date
Americas
EMEA
APAC
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
5.96 B USD
2.96 B USD
2.21 B USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD

Baxter International Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
Total Americas
Americas
Other Countries
U.S. and Puerto Rico plans
International
EMEA
APAC
Europe
Asia Pacific
Latin America and Canada
Emerging markets
Details
Date
United States
Total Americas
Americas
Other Countries
U.S. and Puerto Rico plans
Segment, Geographical, Groups of Countries, Europe
International
EMEA
APAC
Europe
Segment, Geographical, Groups of Countries, Asia Pacific
Asia Pacific
Asia-Pacific
Segment, Geographical, Groups of Countries, Latin America and Canada
Latin America and Canada
Emerging markets
Jan 1, 2018
4.72 B USD
0.00 USD
5.96 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.96 B USD
2.21 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.24 B USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
6.09 B USD
0.00 USD
4.83 B USD
0.00 USD
0.00 USD
2.97 B USD
2.30 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.27 B USD
0.00 USD
Jan 1, 2020
0.00 USD
6.07 B USD
0.00 USD
0.00 USD
4.88 B USD
0.00 USD
0.00 USD
3.13 B USD
2.48 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.19 B USD
0.00 USD
Jan 1, 2021
5.18 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
7.60 B USD
3.55 B USD
2.80 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.25 B USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
7.22 B USD
0.00 USD
0.00 USD
0.00 USD
7.89 B USD
3.71 B USD
2.75 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.43 B USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
7.00 B USD
7.81 B USD
0.00 USD
0.00 USD
4.49 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
3.32 B USD
Jan 1, 2024
0.00 USD
0.00 USD
5.85 B USD
4.79 B USD
0.00 USD
0.00 USD
3.44 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.35 B USD
Jan 1, 2025
6.12 B USD
0.00 USD
0.00 USD
5.12 B USD
0.00 USD
0.00 USD
3.73 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.39 B USD

Baxter International Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Baxter International historical P/E ratio, EBIT multiple, and P/S ratio

Baxter International annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Baxter International shares outstanding

The number of shares of Baxter International was 514 M in 2025. This indicates how many shares Baxter International is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
507.00 M Stocks
Jan 1, 2022
507.00 M Stocks
Jan 1, 2023
507.00 M Stocks
Jan 1, 2024
510.00 M Stocks
Jan 1, 2025
514.00 M Stocks
Jan 1, 2026 (e)
514.00 M Stocks
Jan 1, 2027 (e)
514.00 M Stocks
Jan 1, 2028 (e)
514.00 M Stocks

Baxter International stock splits

In Baxter International's history, there have been no stock splits.

Baxter International Dividend History

38 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.01USDYTD
Feb 27, 20260.01USD 0.0%1/1
20250.52USD 50.0%
Feb 28, 20250.17USD 0.0%1/4
May 30, 20250.17USD 0.0%2/4
Aug 29, 20250.17USD 0.0%3/4
Nov 28, 20250.01USD 94.1%4/4
20241.04USD 10.3%
20231.16USD 0.9%
20221.15USD 6.0%
20211.09USD 13.6%
20200.96USD 12.4%
20190.85USD 16.4%
20180.73USD 19.7%
20170.61USD 20.8%

Baxter International dividend history and estimates

In 2025, Baxter International paid a dividend amounting to 0.52 USD. Dividend means that Baxter International distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
1.09 USD
0.00 USD
Jan 1, 2022
1.15 USD
0.00 USD
Jan 1, 2023
1.16 USD
0.00 USD
Jan 1, 2024
1.04 USD
0.00 USD
Jan 1, 2025
0.52 USD
0.00 USD
Jan 1, 2026 (e)
0.01 USD
0.03 USD
Jan 1, 2027 (e)
0.00 USD
0.04 USD
Jan 1, 2028 (e)
0.00 USD
0.04 USD

Baxter International dividend payout ratio

In 2025, Baxter International had a payout ratio of -27.93%. The payout ratio indicates the percentage of the company's profits that Baxter International distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
42.84 %
Jan 1, 2022
-23.96 %
Jan 1, 2023
22.14 %
Jan 1, 2024
-81.73 %
Jan 1, 2025
-27.93 %
Jan 1, 2026 (e)
2.08 %
Jan 1, 2027 (e)
2.02 %
Jan 1, 2028 (e)
1.87 %

Current Baxter International forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
8.00 % (2)
Hold
64.00 % (16)
Sell
28.00 % (7)
12M Price Target
22.44
Last Price
27.55
Currency
USD
12M Return Potential
-18.55 %
LTM Return
0 %

Baxter International Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
7/31/2026
TD Cowen
TD Cowen
MaintainedHold60
7/31/2026
Stifel
Stifel
MaintainedHold
7/31/2026
Citigroup
Citigroup
UpgradeSellNeutral48
7/28/2026
UBS
UBS
MaintainedNeutral51
7/28/2026
Stifel
Stifel
MaintainedHold
7/27/2026
TD Cowen
TD Cowen
MaintainedHold60
7/15/2026
Goldman Sachs
Goldman Sachs
MaintainedNeutral
7/6/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
5/28/2026
Citigroup
Citigroup
DowngradeNeutralSell48

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Baxter International Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20260.37USD-2.83 BUSD-2026 Q2
4/30/20260.32USD-2.65 BUSD-2026 Q1
2/12/20260.54USD-2.85 BUSD-2025 Q4
4/25/20240.66USD-3.66 BUSD-2024 Q1
2/7/20240.87USD-3.83 BUSD-2023 Q4
7/26/20230.87USD-3.79 BUSD-2023 Q2
4/26/20230.81USD-3.67 BUSD-2023 Q1
2/15/20230.96USD-3.82 BUSD-2022 Q4
10/27/20220.82USD-3.83 BUSD-2022 Q3
7/28/20220.88USD-3.94 BUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Baxter International stock

77/100
69
Environment
80
Social
83
Governance
E

Environment

20
Scope 1 - Direct Emissions351,733
Scope 2 - Indirect emissions from purchased energy384,454
Scope 3 - Indirect emissions within the value chain4,915,054
Total CO₂ emissions736,187
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees47
Percentage of women in management
Percentage of Asian employees8.2
Share of Asian management13.2
Percentage of Hispanic/Latino employees18.8
Hispano/Latino Management share7.5
Percentage of Black employees9.9
Black Management Share3.5
Percentage of white employees60.6
White Management Share73.7
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Baxter International shareholder structure

% Name
15.56876%
BLACKROCK, INC.
BLACKROCK, INC.
12.65251%
PZENA INVESTMENT MANAGEMENT LLC
PZENA INVESTMENT MANAGEMENT LLC
11.22639%
DODGE & COX
DODGE & COX
9.07153%
FMR LLC
FMR LLC
6.57000%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
4.70458%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
...

Baxter International Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
27.99%
36-0781620
36-0781620
SEC ↗
19.40%
2
2
SEC ↗
12.70%
PZENA INVESTMENT MANAGEMENT LLC
PZENA INVESTMENT MANAGEMENT LLC
SEC ↗
12.20%
Baxter International Inc.
Baxter International Inc.
SEC ↗
12.20%
Baxter Healthcare SA
Baxter Healthcare SA
SEC ↗
11.33%
Wellington Management Group LLP
Wellington Management Group LLP
SEC ↗
11.20%
Dodge & Cox
Dodge & Cox
SEC ↗
10.80%
10.8 % (2)
10.8 % (2)
SEC ↗
10.36%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
10.36%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗

Baxter International Executives and Management Board

19 members · avg. age 61 · 37 % women

HK

Ms. Heather Knight (53)

Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies

6.60 M USD

Management

JG

Mr. Joel Grade (54)

Chief Financial Officer, Executive Vice President

6.51 M USD
DR

Mr. David Rosenbloom (65)

Executive Vice President, General Counsel

5.56 M USD
AS

Mr. Alok Sonig (52)

Executive Vice President, Group President - Pharmaceuticals

5.35 M USD
JM

Dr. Jeanne Mason (69)

Chief Human Resources Officer, Executive Vice President

4.14 M USD
AH

Mr. Andrew Hider (48)

President, Chief Executive Officer, Director · since 2025

JB

Mr. James Borzi (62)

Executive Vice President and Chief Supply Chain Officer

Board of Directors

DS

Mr. D. Brent Shafer (67)

Non-Executive Chairman of the Board · since 2022

386,986.00 USD
SO

Dr. Stephen Oesterle (74)

Independent Director

371,986.00 USD
DW

Dr. David Wilkes (68)

Independent Director

371,521.00 USD
NS

Ms. Nancy Schlichting (70)

Lead Independent Director

369,521.00 USD
CS

Ms. Catherine Smith (61)

Independent Director

359,986.00 USD
AM

Ms. Amy Mcbride-Wendell (64)

Independent Director

354,986.00 USD

Baxter International Supply Chain

Baxter International Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
MacroGenics
Customer·Biotechnology·US
0.23
-0.70
0.61
0.72
0.12
0.35
#Nameβ 1YTrend
1
Perella Weinberg A
Supplier·Capital Markets·US
0.73
-0.49
0.80
0.85
0.36
2
Miromatrix Medical
Supplier·Customer·Life Sciences Tools & Services·US
0.53
0.77
-0.20
0.27
3
Takeda Pharmaceutical Company Limited
Supplier
0.38
-0.20
-0.40
-0.28
-0.25
4
bioMérieux S.A.
Supplier
0.17
-0.56
0.76
0.74
0.31
5
Syngene International Limited
Supplier
0.15
-0.59
-0.26
0.02
-0.03
-0.35

Frequently asked questions about Baxter International

The business model of Baxter International Inc. is centered around developing, manufacturing, and marketing a broad portfolio of products and therapies for patients with life-threatening medical conditions. Baxter provides essential healthcare solutions across the clinical areas of critical care, nutrition, renal, and pharmaceuticals. The company's products and services aim to support healthcare professionals in improving patient outcomes and enhancing overall medical care. Baxter International Inc. operates globally and collaborates with various stakeholders in the healthcare industry to deliver innovative solutions that address unmet medical needs.

Baxter International Inc is primarily active in the healthcare industry. As a global leader in medical technology, Baxter specializes in providing innovative solutions for hospitals, clinics, and home care settings. The company focuses on various segments within healthcare, including renal care, acute therapies, and medication delivery. With a wide range of products and services, Baxter plays a vital role in enhancing patient care and improving outcomes across the healthcare continuum.

The main competitors of Baxter International Inc in the market include Johnson & Johnson, Fresenius Medical Care AG & Co. KGaA, and Becton, Dickinson and Company.

Baxter International Inc., based in Deerfield, Illinois, is a renowned American healthcare company with a rich history and impressive background. Established in 1931, Baxter has consistently excelled in developing and manufacturing medical products and technologies, specializing in biotherapeutics, renal care, and medication delivery. With a commitment to advancing patient care, Baxter has grown to become a global leader in the healthcare industry. Over the years, the company has introduced numerous innovative and life-saving solutions, including intravenous therapies, vaccines, and devices for dialysis. With its dedication to meeting critical healthcare needs worldwide, Baxter International Inc. continues to be a prominent player in the medical field.

Over the years, Baxter International Inc has achieved numerous significant milestones, solidifying its position in the healthcare industry. One notable achievement is the development of innovative medical products and therapies that have improved patient outcomes globally. Baxter International Inc has also demonstrated its commitment to sustainability by implementing eco-friendly practices and receiving recognition for its environmental efforts. Additionally, the company has expanded its international presence through strategic acquisitions and collaborations, further strengthening its global footprint. Overall, Baxter International Inc's dedication to innovation, sustainability, and global expansion has propelled it to become a leading player in the healthcare sector.

Baxter International Inc is primarily present in numerous countries and regions globally. This healthcare company operates in North America, including the United States, Canada, and Mexico. It has a strong presence in Europe, spanning countries like Germany, France, Italy, and the United Kingdom. Baxter International Inc also has significant operations in the Asia-Pacific region, with a focus on countries such as China, Japan, India, and Australia. Additionally, the company maintains a presence in Latin America, including Brazil, Argentina, and Chile. With its extensive global reach, Baxter International Inc serves a diverse range of markets and communities worldwide.

Baxter International Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on improving patient outcomes, the company strives to provide high-quality healthcare products and services worldwide. Baxter International Inc is committed to advancing medicine through its diverse portfolio of medical devices, pharmaceuticals, and biotechnology solutions. As a global leader, Baxter International Inc consistently emphasizes ethical practices, regulatory compliance, and sustainability. By actively investing in research and development, Baxter International Inc aims to drive positive changes in healthcare and enhance the well-being of patients globally.

Analysts currently set an average price target of 23.61 USD for the Baxter International stock (median: 22.44 USD), implying -14.3 % versus the latest price. The consensus is based on 25 analyst ratings.

25 analysts currently rate the Baxter International stock: 2 recommend buying, 16 holding and 7 selling. For 2026, analysts expect Baxter International to generate revenue of 11.35 B USD and earnings per share of 1.91 USD.

Converted at the current exchange rate, the Baxter International share trades at 23.39 EUR (27.01 USD).

The Baxter International share (BAX) is listed on 11 stock exchanges, including: NYSE (BAX), XETRA (BTL.DE), Frankfurt (BTL.F), München (BTL.MU), Düsseldorf (BTL.DU), Hamburg (BTL.HM), London (0QK8.L), London (0QK8.L).

Baxter International Inc is a US-based company operating in the healthcare and pharmaceutical sectors. The company provides medical products and services to supply patients worldwide. It is divided into three main business segments: Hospital Products, Renal Products, and Clinical Nutrition. Hospital Products is the largest segment and offers a variety of products including infusion solutions, injectables, medical devices, and concentrated solutions. Renal Products includes products and services for dialysis treatment, home hemodialysis, and acute kidney failure. Baxter also manufactures dialysis machines and accessories, as well as dialysis containers and concentrates. Clinical Nutrition also offers specialized nutrition products and preparations for parenteral nutrition. The company is a leading provider of parenteral nutrition products, including amino acids, carbohydrates, fat emulsions, and electrolytes. Baxter International also manufactures blood products such as plasma products and clotting factors. Additionally, the company offers specially processed biological products that can be used to treat conditions such as hemophilia and immunodeficiency. The company also operates an advanced life sciences business focused on drug development and medical devices. Baxter International collaborates with numerous global partners and develops innovative technologies in oncology and other areas of medical research. Baxter International is a company focused on proactive solutions to improve patient care and provide safe, effective, and high-quality medical products. The company is also committed to sustainable development and environmental protection by optimizing its materials and energy sources and continuously improving its production technology. In summary, Baxter International is a company dedicated to the development and provision of high-quality medical products and services. Through its various business segments, the company offers a wide range of products and services for different medical conditions to improve the medical care of patients worldwide. The company has also committed to sustainable and environmentally friendly production to fulfill its responsibility to society and the environment.

The expected revenue of Baxter International is 11.35 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Baxter International is 980.13 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Baxter International is currently 14.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Baxter International stock.

The price-to-sales ratio (P/S) of Baxter International is currently 1.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Baxter International stock.

The Eulerpool Quality Score for Baxter International is 1/10.

The ISIN of Baxter International is US0718131099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Baxter International is 853815. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Baxter International is BAX. The ticker symbol is used to trade Baxter International shares on the stock exchange.

Over the past 12 months, Baxter International paid a dividend of 0.52 USD . This corresponds to a dividend yield of about 1.93 %. For the coming 12 months, Baxter International is expected to pay a dividend of 0.04 USD.

The current dividend yield of Baxter International is 1.93 %.

Baxter International pays a dividend, distributed in the months of , , , .

Baxter International paid dividends every year for the past 37 years.

For the upcoming 12 months, dividends amounting to 0.04 USD are expected. This corresponds to a dividend yield of 0.15 %.

Baxter International is assigned to the 'Health' sector.

To receive the latest dividend of Baxter International from amounting to 0.01 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Baxter International distributed 1.04 USD as dividends.

The dividends of Baxter International are distributed in USD.